BioMarin Pharmaceutical Gets DOJ Subpoena for Documents Related to Vimizim, Naglazyme
By Denny Jacob
BioMarin Pharmaceutical received a subpoena from the U.S. Justice Department for certain documents regarding sponsored testing programs related to vimizim and naglazyme.
The biotechnology company said it has produced the requested documents in response to the subpoena and is cooperating fully, according to a regulatory filing. It added that it is unable to make any assurance regarding the outcome of the investigation by the DOJ and the potential impact such an investigation would have on aspects of the company.
A representative for the DOJ didn't immediately respond to a request for comment.
Vimizim is a treatment of MPS IVA, a lysosomal storage disorder. Naglazyme is a treatment for patients with MPS VI, a life-threatening genetic disease.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
February 26, 2024 14:23 ET (19:23 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
After Earnings, Is Berkshire Hathaway Stock a Buy, a Sell, or Fairly Valued?
-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
Berkshire Hathaway Earnings: Strong Insurance Results Continue to Lift Revenue and Profitability
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom